Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
33
APYX Quote, Financials, Valuation and Earnings
Last price:
$1.58
Seasonality move
:
5.24%
Day range:
$1.54 - $1.61
52-week range:
$0.97 - $2.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.12x
P/B ratio:
5.35x
Volume:
88.6K
Avg. volume:
78.2K
1-year change:
-37.2%
Market cap:
$59.1M
Revenue:
$52.3M
EPS (TTM):
-$0.83
Analysts' Opinion
-
Consensus RatingApyx Medical has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Apyx Medical has an estimated upside of 80.47% from its current price of $1.57.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $1.57.
Fair Value
-
According to the consensus of 0 analysts, Apyx Medical has 80.47% upside to fair value with a price target of -- per share.
APYX vs. S&P 500
-
Over the past 5 trading days, Apyx Medical has underperformed the S&P 500 by -4.65% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Apyx Medical does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Apyx Medical revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Apyx Medical reported revenues of $11.5M.
Earnings Growth
-
Apyx Medical earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Apyx Medical reported earnings per share of -$0.14.
Enterprise value:
65.1M
EV / Invested capital:
1.44x
Price / LTM sales:
1.12x
EV / EBIT:
--
EV / Revenue:
1.34x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-3.64x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$29.3M
Return On Assets:
-42.39%
Net Income Margin (TTM):
-58.59%
Return On Equity:
-132.8%
Return On Invested Capital:
-56.85%
Operating Margin:
-31.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $48.7M | $50.3M | $48.5M | $12M | $11.5M | |
| Gross Profit | $33M | $33.1M | $29.3M | $8M | $7M | |
| Operating Income | -$19.3M | -$20.1M | -$21.6M | -$4.6M | -$3.6M | |
| EBITDA | -$17.9M | -$15.6M | -$22.3M | -$4.2M | -$3.1M | |
| Diluted EPS | -$0.56 | -$0.43 | -$0.83 | -$0.13 | -$0.14 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $67.7M | $59.9M | $46.3M | $50.2M | $52.2M | |
| Total Assets | $75.4M | $67.8M | $55.3M | $59.4M | $60.7M | |
| Current Liabilities | $9.6M | $11.7M | $11.2M | $10.3M | $9.6M | |
| Total Liabilities | $11.1M | $13.1M | $13.1M | $25.9M | $49.5M | |
| Total Equity | $64.3M | $54.7M | $42.2M | $33.6M | $11.2M | |
| Total Debt | $140K | -- | -- | $9M | $33.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$15.5M | -$7.6M | -$17.3M | $3.7M | -$4.4M | |
| Cash From Investing | -$1.2M | $6.7M | -$570K | -$174K | -$153K | |
| Cash From Financing | $188K | $8.3M | $23.8M | $164K | -$5K | |
| Free Cash Flow | -$16.7M | -$8.1M | -$17.9M | $3.5M | -$4.6M | |
APYX
Sector
Market Cap
$59.1M
$44.6M
Price % of 52-Week High
56.07%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-37.2%
-29.09%
Beta (5-Year)
1.273
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.66
200-day SMA
Buy
Level
$1.39
Bollinger Bands (100)
Buy
Level
1.12 - 1.5
Chaikin Money Flow
Buy
Level
38.9M
20-day SMA
Sell
Level
$1.63
Relative Strength Index (RSI14)
Buy
Level
50.85
ADX Line
Sell
Level
13.78
Williams %R
Neutral
Level
-69.0909
50-day SMA
Buy
Level
$1.40
MACD (12, 26)
Buy
Level
0.06
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
48.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.8291)
Sell
CA Score
(Annual)
Level (-1.4884)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.1668)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
Stock Forecast FAQ
In the current month, APYX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The APYX average analyst price target in the past 3 months is --.
-
Where Will Apyx Medical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Apyx Medical share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Apyx Medical?
Analysts are divided on their view about Apyx Medical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Apyx Medical is a Sell and believe this share price will drop from its current level to --.
-
What Is Apyx Medical's Price Target?
The price target for Apyx Medical over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is APYX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Apyx Medical is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of APYX?
You can purchase shares of Apyx Medical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Apyx Medical shares.
-
What Is The Apyx Medical Share Price Today?
Apyx Medical was last trading at $1.58 per share. This represents the most recent stock quote for Apyx Medical. Yesterday, Apyx Medical closed at $1.57 per share.
-
How To Buy Apyx Medical Stock Online?
In order to purchase Apyx Medical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
